Lack of Association Between MDR1 C3435T Polymorphism and Chemotherapy Response in Advanced Breast Cancer Patients: Evidence from Current Studies

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2011 Dec 14

PMID 22160574

Citations 7

Authors

Guodi Chen

Sheng Quan

Qiongge Hu

Liancong Wang

Xiaoping Xia

Jing Wu

Affiliations

Soon will be listed here.

Abstract

The transmembrane transport of anticancer drugs is mainly regulated by P-glycoprotein encoded by the human multidrug resistance gene 1 gene (MDR1). Since there were controversies regarding the association between MDR1 C3435T polymorphism and response to chemotherapy among patients with advanced breast cancer, a meta-analysis of the link was conducted. A total of 7 studies consist of 464 advanced breast cancer patients relating MDR1 C3435T polymorphism to the response of chemotherapy were included in this meta-analysis. The main analysis revealed a lack of association between the MDR1 C3435T and response to chemotherapy, with odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) of 1.37 (95% CI: 0.78-2.40), 1.17 (95% CI: 0.69-2.01), 1.18 (95% CI: 0.76-1.84) and 1.61 (95% CI: 0.70-3.68) for homozygous comparison, heterozygous comparison, dominant model and recessive model, respectively. The subgroup analysis by ethnicity did not change the pattern of results, with ORs of 0.99 (95% CI: 0.11-9.07), 0.68 (95% CI: 0.29-1.60), 0.81 (95% CI: 0.36-1.85) and 1.51 (95% CI: 0.77-2.96), in homozygous comparison, heterozygous comparison, dominant model and recessive model, respectively in Caucasian, and 1.50 (95% CI: 0.75-3.03), 1.72 (95% CI: 0.85-3.47), 1.59 (95% CI: 0.90-2.80) and 2.29 (95% CI: 0.51-10.35), respectively in Asian. The available evidence indicates that MDR1 C3435T polymorphism cannot be considered as a reliable predictor of response to chemotherapy in patients with advanced breast cancer.

Citing Articles

No Association between ABCB1 G2677T/A or C3435T Polymorphisms and Survival of Breast Cancer Patients-A 10-Year Follow-Up Study in the Polish Population.

Toton E, Jacczak B, Barczak W, Jagielski P, Gryczka R, Holysz H Genes (Basel). 2022; 13(5).

PMID: 35627114 PMC: 9141033. DOI: 10.3390/genes13050729.

C3435T polymorphism in the gene and breast cancer risk in northeastern Mexico.

Jaramillo-Rangel G, Ortega-Martinez M, Cerda-Flores R, Barrera-Saldana H Int J Clin Exp Pathol. 2020; 11(2):904-909.

PMID: 31938182 PMC: 6958023.

ABCB1 (rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a meta-analysis.

Zhou Z, Chen Q, Zuo D, Wang H, Hua Y, Cai Z Int J Clin Exp Med. 2015; 8(1):265-72.

PMID: 25784996 PMC: 4358451.

Investigation on XRCC1 genetic polymorphism and its relationship with breast cancer risk factors in Chinese women.

Zheng L, Yang F, Zhang X, Zhu J, Zhou P, Yu F Med Oncol. 2013; 30(4):738.

PMID: 24277466 DOI: 10.1007/s12032-013-0738-x.

Association analysis between MDR1 genetic variant and breast cancer risk factors in Chinese Han population.

Hu Y, Wang J, Tao H, Wang H, Zhang X, Cheng Y Med Oncol. 2013; 30(3):683.

PMID: 23925666 DOI: 10.1007/s12032-013-0683-8.

References

Zhang B, Sun T, Zhang B, Zheng S, Lu N, Xu B . Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J (Engl). 2011; 124(2):199-204. View

Hoffmeyer S, Burk O, von Richter O, Arnold H, Brockmoller J, Johne A . Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000; 97(7):3473-8. PMC: 16264. DOI: 10.1073/pnas.97.7.3473. View

Ashariati A . Polymorphism C3435T of the MDR-1 gene predict response to preoperative chemotherapy in locally advanced breast cancer with Her2/neu expression. Acta Med Indones. 2009; 40(4):187-91. View

Levine M, Whelan T . Adjuvant chemotherapy for breast cancer--30 years later. N Engl J Med. 2006; 355(18):1920-2. DOI: 10.1056/NEJMe068204. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

George J, Dharanipragada K, Krishnamachari S, Chandrasekaran A, Sam S, Sunder E . A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer. 2009; 9(3):161-5. DOI: 10.3816/CBC.2009.n.026. View

Schwab M, Eichelbaum M, Fromm M . Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2002; 43:285-307. DOI: 10.1146/annurev.pharmtox.43.100901.140233. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

Maffioli M, Camos M, Gaya A, Hernandez-Boluda J, Alvarez-Larran A, Domingo A . Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res. 2010; 35(8):1014-9. DOI: 10.1016/j.leukres.2010.12.004. View

10.

Tahara T, Arisawa T, Shibata T, Hirata I, Nakano H . Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. J Gastroenterol Hepatol. 2007; 22(10):1678-82. DOI: 10.1111/j.1440-1746.2007.04848.x. View

11.

Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y . Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001; 297(3):1137-43. View

12.

Burger H, Foekens J, Look M, Meijer-Van Gelder M, Klijn J, Wiemer E . RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res. 2003; 9(2):827-36. View

13.

Chevillard S, Lebeau J, Pouillart P, De Toma C, Beldjord C, Asselain B . Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res. 1998; 3(12 Pt 1):2471-8. View

14.

Rodrigues F, Santos R, Melo M, Silva M, Oliveira A, Rozenowicz R . Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet Mol Res. 2008; 7(1):177-83. DOI: 10.4238/vol7-1gmr400. View

15.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

16.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

17.

Zintzaras E, Ziogas D, Kitsios G, Papathanasiou A, Lau J, Raman G . MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics. 2009; 10(8):1285-94. DOI: 10.2217/pgs.09.59. View

18.

Ni L, Li J, Miao K, Qiao C, Zhang S, Qiu H . Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 2010; 28(1):265-9. DOI: 10.1007/s12032-010-9456-9. View

19.

Chang H, Rha S, Jeung H, Im C, Ahn J, Kwon W . Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. 2008; 20(2):272-7. DOI: 10.1093/annonc/mdn624. View

20.

Illmer T, Schuler U, Thiede C, Schwarz U, Kim R, Gotthard S . MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002; 62(17):4955-62. View